Actualités

Intuitive Surgical (NASDAQ: ISRG) shares fell about 11% on Friday after the robotic surgery company reported second-quarter results that topped Wall Street expectations but disappointed investors with slower US procedure growth and a cautious full-year outlook. The company reported second...

According to TheFly, Citi lowered its price target to $500 from $590 and keeps a ‘Buy’ rating.

Investing.com - U.S. stock index futures fell sharply on Friday, pointing to a second straight day of losses on Wall Street as investors continued to reassess lofty technology valuations following a string of disappointing corporate updates tied to artificial intelligence spending.

Stock Market Today: The Dow Jones index dropped Friday as Netflix stock plunged on earnings. SpaceX shares sold off on a canceled test flight.

The benchmark US stock measures were pointing lower before the open Friday as a sell-off in semicond

Intuitive Surgical stock falls sharply after earnings, but this analyst believes investors are missing part of the picture.

Ahead of the bell Wall Street looks set to be headed for the red with US stock futures falling on Friday, leaving the major indices on course for weekly losses as the semiconductor sell-off rolled on. Dow Jones futures slipped 0.6%, and S&P 500 contracts dropped around...

Intuitive Surgical (ISRG) shares fell early Friday as growth in the company's da Vinci robotic surge

FEATURE Tech was getting hit again on Friday as investors carried on selling chip makers and other artificial-intelligence stocks. Futures tracking the slumped 1.8%. The and were both also on track to open lower.

Intuitive Surgical Inc. (NASDAQ:ISRG) shares fell sharply after the medical technology company released second-quarter results that topped Wall Street forecasts but issued a full-year procedure growth outlook that failed to meet investor expectations.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Intuitive Surgical is a leader in surgical robotics, and the stock has a history of deep drawdowns.

Although the revenue and EPS for Intuitive Surgical (ISRG) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Moby summary of Intuitive Surgical, Inc.'s Q2 2026 earnings call

Intuitive Surgical (NASDAQ:ISRG) reported a solid second quarter of 2026, with management pointing to continued global adoption of its da Vinci, da Vinci SP and Ion platforms, even as U.S. procedure growth moderated and China remained challenging. Chief Executive Officer Dave Rosa said total proced

Intuitive Surgical (ISRG) delivered earnings and revenue surprises of +12.90% and +3.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Intuitive Surgical issued lackluster procedure guidance for the year on Thursday, leading the stock to take a dive.

Medical technology company Intuitive Surgical (NASDAQ:ISRG) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 18.5% year on year to $2.89 billion. Its non-GAAP profit of $2.80 per share was 11.9% above analysts’ consensus estimates. Stock drop is primarily driven by recent declines in overall surgery volumes, which were reported by major healthcare providers, as well as a recent Class II recall of certain da Vinci surgical components.

Wall Street is betting big on Ambarella's Physical AI opportunity.

Abbott’s (ABT) latest financial disclosure reveals a significant strategic evolution that market participants often overlook amidst the focus on quarterly beats. The company is actively executing a structural pivot, shifting its capital allocation and growth dependency away from the volatile Nutrition segment toward high-margin, innovation-led MedTech and specialized diagnostics.

In April 2026, Intuitive Surgical voluntarily initiated an ongoing Class II worldwide recall of certain da Vinci surgical system components after discovering an E-brake retainer pin issue that could impede emergency braking or cause uncontrolled column motion, with 454 affected units identified by specific serial numbers. This safety action, alongside growing attention on Intuitive’s AI-enabled da Vinci 5 rollout and competitive pressures in robotic surgery, raises fresh questions about how...

Today Earnings (a.m): UnitedHealth, GE Aerospace, U.S. Bancorp, Citizens Financial, Abbott Laboratories, State Street, Taiwan Semiconductor Manufacturing Earnings (p.m.): Netflix, Intuitive Surgical Economic data: Weekly jobless claims, Philadelphia Fed business-outlook survey, retail sales, pending home sales index, business inventories Fed speakers: Fed Vice Chair Philip Jefferson is expected to speak, as is Dallas Fed President Lorie Logan.

Intuitive Surgical's powerful growth is running headlong into some serious market challenges, and how management framed the collision tells you everything about the real risks.

Johnson & Johnson's post-earnings pullback follows a revenue and EPS beat, raised guidance, and analyst price target increases, with talc litigation remaining the key risk to watch.

ISRG is countering rising global robotic surgery competition with tiered platforms, AI features and a broad ecosystem focused on value over price.

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the 8 Worst Blue Chip Stocks to Buy Now. On July 9, 2026, BMO Capital analyst Vik Chopra initiated coverage of Intuitive Surgical, Inc. (NASDAQ:ISRG) with an Outperform rating and $518 price target. Chopra said the da Vinci 5 upgrade cycle remains in the early innings, procedure growth […]

The robotic surgery company has posted earnings beats in its past four quarters. Can it make it five in a row?

Johnson & Johnson stock dipped early Wednesday, though the healthcare giant beat second-quarter forecasts and raised its outlook.

Johnson & Johnson raised its full-year guidance on the back of better-than-expected second-quarter earnings as strength in its oncology portfolio helped offset falling sales for its former blockbuster drug, Stelara. The drugmaker on Wednesday reported adjusted earnings of $2.90 a share, beating the $2.85 a share analysts had anticipated. J&J logged $25 billion in sales, in line with Wall Street estimates and up 6% from the same period last year.

And Goldman Sachs may be right.